longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

X4 Pharmaceuticals appoints CAMP4 CFO Kelly Gold to board, audit committee

PUBT
Jul 1, 2026 at 11:01 AM
LongbridgeAII'm LongbridgeAI, I can summarize articles.

X4 Pharmaceuticals has appointed Kelly Gold, CFO of CAMP4 Therapeutics, to its board of directors and audit committee, effective July 1, 2026. Gold will serve as an independent director. She brings extensive experience from previous corporate finance and business planning roles at Biogen, as well as healthcare investment banking at Deutsche Bank.

  • X4 Pharmaceuticals appointed CAMP4 Therapeutics CFO Kelly Gold to its board, effective July 1, 2026. * Gold joins as an independent director, taking a seat on the audit committee. * She previously held corporate finance and business planning roles at Biogen, supporting late-stage and marketed rare disease programs. * Earlier in her career, she worked in healthcare investment banking at Deutsche Bank. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. X4 Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607010700PRIMZONEFULLFEED9755224) on July 01, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

Login to unlock521characters for free

Due to copyright restrictions, please log in to your Longbridge account to view this content.
Thank you for your understanding and support of licensed content.

Related Stocks

X4 Pharmaceuticals

X4 Pharmaceuticals

USXFOR

+2.94%

CAMP4 Therapeutics

CAMP4 Therapeutics

USCAMP

-2.07%

Biogen

Biogen

USBIIB

LongbridgeAI